|
ИСТИНА |
Войти в систему Регистрация |
ИСТИНА ИНХС РАН |
||
HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?статья
Статья опубликована в высокорейтинговом журнале
Информация о цитировании статьи получена из
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 5 июня 2024 г.
- Авторы: Kekeeva T., Andreeva Y., Tanas A., Kalinkin F., Khokhlova S., Tikhomirova T., Tyulyandina A., Popov A., Kuzmenko M., Volkonsky M., Chernorubashkina N., Saevets V., Dmitriev V., Nechushkina V., Vedrova O., Andreev S., Kutsev S., Strelnikov V.
- Журнал: International Journal of Molecular Sciences
- Том: 24
- Номер: 13
- Год издания: 2023
- Издательство: MDPI
- Местоположение издательства: Basel, Switzerland
- Номер статьи: 10497
- DOI: 10.3390/ijms241310497
- Аннотация: Assessment of homologous recombination deficiency (HRD) status is now essential for ovarian cancer patient management. The aim of our study was to analyze the influence of ethnic variations, tumor purity, and neoadjuvant chemotherapy (CT) on the determination of HRD scores as well as to evaluate feasibility of HRD testing with the Amoy HRD Focus Assay in routine clinical practice. The HRD status, including the BRCA status and genomic scar score (GSS), was analyzed in 452 ovarian cancer specimens. The successful rate of HRD testing was 86% (388/452). The BRCA mutational rate was 29% (114/388); 252 samples (65%) were classified as HRD-positive. Our data demonstrate the feasibility of internal HRD testing by the AmoyDx HRD Focus Panel for high-grade serous ovarian cancer (HGSOC), showing results similar to other methods. The HRD rate in the Russian population is very similar to those of other European populations, as is the BRCA mutation frequency. The most substantial contribution to HRD level diversity is testing criteria depending on intrahospital arrangements. The analysis shows that biallelic BRCA alterations had higher GSS compared with those with monoallelic inactivation, consistent with positive HRD status. The study indicates that grades 1–2 of the pathological response caused by chemotherapy affect HRD scores and suggests controlling for tumor purity of 40% or more as a critical factor for GSS measurement.Keywords: homologous recombination deficiency; BRCA mutation; genomic instability score; tumor purity; pathological response
- Добавил в систему: Кубасова Ирина Юрьевна